The Future of Drug Development - Panel Discussion

Friday October 27, 2017
1:30 PM – 2:30 PM


David Schenkein, MD


35 Kneeland St
Boston, MA 02111

GEO: ,

Directions & Parking

Floor 8 Conference Room


The Sackler Community is invited to attend a Panel Discussion on "The Future of Drug Development" with special guest David Schenkein, MD. Dr. Schenkein joined Agios in August 2009 as the CEO, which recently received FDA approval for a novel therapy for acute leukemia. He has been a Hematologist and Medical Oncologist for more than 20 years. Dr. Schenkein was a full time member of Tufts Medical Center faculty until 2001 when he joined Millennium and led the approval of bortezomib (Velcade,worldwide $1.3B sales in annual sales). Currently, Dr. Schenkein serves as an adjunct attending physician in Hematology at Tufts Medical Center. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the Senior Vice President, Clinical Hematology/Oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. Additionally, esteemed Tufts faculty Dr. Kenneth Kaitin, Director of the Tufts Center for the Study of Drug Development, and Dr. Andreas Klein, Associate Chief, Division of Hematology/Oncology, will participate in the panel discussion.

Contact Information

Rachael Bailey

Submit a correction to this event


You are currently viewing the calendar with some filters applied. Would you like to subscribe to the calendar with those filters applied, or the entire calendar?

Full Feed Filtered Feed